Genetic Signatures Ltd (GSS) - Total Liabilities
Based on the latest financial reports, Genetic Signatures Ltd (GSS) has total liabilities worth AU$4.95 Million AUD (≈ $3.50 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. For the complete balance sheet picture, see GSS total asset value.
Genetic Signatures Ltd - Total Liabilities Trend (2013–2025)
This chart illustrates how Genetic Signatures Ltd's total liabilities have evolved over time, based on quarterly financial data. See Genetic Signatures Ltd (GSS) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Genetic Signatures Ltd Competitors by Total Liabilities
The table below lists competitors of Genetic Signatures Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mynd.ai, Inc.
NYSE MKT:MYND
|
USA | $203.97 Million |
|
Future Retail Limited
NSE:FRETAIL
|
India | Rs12.21 Billion |
|
Asuransi Jiwa Syariah Jasa Mitra Abadi Tbk PT
JK:JMAS
|
Indonesia | Rp216.34 Billion |
|
DatChat Inc
NASDAQ:DATS
|
USA | $838.99K |
|
NFL Biosciences SAS
PA:ALNFL
|
France | €2.60 Million |
|
Blueberry NFT CO.LTD
KQ:044480
|
Korea | ₩22.40 Billion |
|
Edinburgh Investment Trust
LSE:EDIN
|
UK | GBX121.94 Million |
|
Gold Springs Resource Corp
TO:GRC
|
Canada | CA$3.44 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Genetic Signatures Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. Check GSS asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 3.60 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genetic Signatures Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genetic Signatures Ltd (2013–2025)
The table below shows the annual total liabilities of Genetic Signatures Ltd from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$4.54 Million ≈ $3.21 Million |
-26.62% |
| 2024-06-30 | AU$6.18 Million ≈ $4.38 Million |
+0.32% |
| 2023-06-30 | AU$6.16 Million ≈ $4.36 Million |
+27.04% |
| 2022-06-30 | AU$4.85 Million ≈ $3.43 Million |
+3.08% |
| 2021-06-30 | AU$4.71 Million ≈ $3.33 Million |
+24.33% |
| 2020-06-30 | AU$3.79 Million ≈ $2.68 Million |
+142.54% |
| 2019-06-30 | AU$1.56 Million ≈ $1.10 Million |
+29.07% |
| 2018-06-30 | AU$1.21 Million ≈ $855.77K |
+1.65% |
| 2017-06-30 | AU$1.19 Million ≈ $841.86K |
-7.30% |
| 2016-06-30 | AU$1.28 Million ≈ $908.13K |
+72.71% |
| 2015-06-30 | AU$743.14K ≈ $525.82K |
+100.59% |
| 2014-06-30 | AU$370.48K ≈ $262.13K |
-91.24% |
| 2013-06-30 | AU$4.23 Million ≈ $2.99 Million |
-- |
About Genetic Signatures Ltd
Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. It offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, extended respiratory, atypical respiratory, Measles, Mumps, a… Read more